Skip to main content
SpringerLink
Log in

Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Taxanes have been shown to interact with anti-apoptotic proteins. In the present study we investigated whether the addition of taxane in combination with DNA damaging drugs can further enhance tumor shrinkage in cases with incomplete response to radiotherapy. Since the dose of docetaxel in combination with carboplatin is not known, the above hypothesis was tested in the context of a dose escalation phase I study.

Twenty-eight patients with locally advanced chest or pelvic tumors, showing residual disease on CT scans performed 40 d following docetaxel radio-chemotherapy, were recruited in a dose escalation protocol of docetaxel/carboplatin supported with amifostine and GM-CSF. The starting dose of docetaxel was 40 mg/m2 every 2 weeks. Carboplatin dose was calculated using the Calvert formula and was escalated in cohorts of 4 patients (starting dose AUC2 every two weeks; AUC0.5 increments up to AUC3). Thereafter the docetaxel dose was increased to 50 and 60 mg/m2, while carboplatin was escalated (by AUC0.5 increments) starting from AUC3 and AUC4 respectively. Amifostine (600 mg/m2) was administered i.v. before carboplatin and GM-CSF (480μg) was injected s.c. on days 5, 6 and 10, 11 of each cycle. Six cycles were given and response was assessed 2 weeks after the end of chemotherapy.

None out of four patients treated in the 6th dose level cohort (50mg/m2 of docetaxel and AUC4 of carboplatin every 2 weeks) showed any grade 2–4 hematologic toxicity. Mild non-hematologic toxicity such as neuropathy, leg edema, pleural effusion, pyrexia, alopecia grade 2 and hypersensitivity was observed in 4–12% of patients. Out of four patients treated in a 7th cohort (docetaxel 60mg/m2 and carboplatin AUC4), one developed grade IV neutropenia and two developed grade 3 severe asthenia requiring treatment delay for 2 weeks. Out of 11 patients with PR following docetaxel radio-chemotherapy, 7 (63%) showed CR after docetaxel/carboplatin additional chemotherapy. Eight out of 17 patients with MR following docetaxel radio-chemotherapy showed PR (47%) and one showed CR (6%) after additional chemotherapy.

High dose combined docetaxel (50 mg/m2) and carboplatin (AUC4) chemotherapy can be safely administered on a two-weekly basis if supported with amifostine and GM-CSF. Such an additional therapy may be important in patients with incomplete response after chemo-RT. Broad spectrum cytoprotection with amifostine and GM-CSF may also contribute to the reduction of incidence of neurosensory reactions and asthenia in patients treated with taxanes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smythe JF, Kris MG. The development of docetaxel (Taxotere) in non small cell lung cancer. Semin Oncol 1997; 24(Suppl 14).

  2. Francis Pet al. Phase II trial of docetaxel in patients with platinum refractory advanced ovarian cancer.J Clin Oncol 1994;12: 2301–2308.

    Article  CAS  PubMed  Google Scholar 

  3. Fumoleau Pet al. A multicentre phase II study of the efficacy and safety of docetaxel as first line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.Ann Oncol 1996;7: 165–171.

    Article  CAS  PubMed  Google Scholar 

  4. Skarlos DVet al. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study.Eur J Cancer 1996;32: 421–428.

    Article  Google Scholar 

  5. Bunn PA. Review of therapeutic trials of carboplatin in lung cancer.Sem Oncol 1989;16(Suppl 5): 27–33.

    Google Scholar 

  6. Johnson DHet al. Paclitaxel plus carboplatin in advanced non small cell lung cancer: a phase II trial.J Clin Oncol 1996;14: 2054–2060.

    Article  CAS  PubMed  Google Scholar 

  7. Bookman MAet al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.J Clin Oncol 1996;14: 1895–1902.

    Article  CAS  PubMed  Google Scholar 

  8. Shea TC. High dose carboplatin plus paclitaxel with granulocyte colony stimulating factor and peripheral blood stem cell support in non small cell lung cancer.Cancer Chemother Pharmacol 1997;40(Suppl): 74–78.

    Article  Google Scholar 

  9. Giannakakis Tet al. Phase I/II study of docetaxel and carboplatin as 1st line chemotherapy in advanced non small cell lung cancer (NSCLC). Preliminary results.Proc Am Soc Clin Oncol 1998;17: 1870.

    Google Scholar 

  10. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol induced apoptosis and phosphorylation of Bcl 2 protein involves c Raf 1 and represents a novel c Raf 1 signal transduction pathway.Cancer Res 1996;56: 1851–1854.

    CAS  PubMed  Google Scholar 

  11. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl 2 phosphorylation and death of prostate cancer cells.Cancer Res 1996;56: 1253–1255.

    CAS  PubMed  Google Scholar 

  12. Geuritte Voegelein Fet al. Relationships between the structure of Taxol analogues and their antimitotic activity.J Med Chem 1991;34: 992–998.

    Article  Google Scholar 

  13. Wang THet al. Microtubule interfering agents activate c Jun N terminal kinase/stress activated protein kinase through both Ras and apoptosis signal regulating kinase pathways.J Biol Chem 1998;273: 4928–4936.

    Article  CAS  PubMed  Google Scholar 

  14. Wahl AFet al. Loss of normal p 53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis.Nat Med 1996;2: 72–79.

    Article  CAS  PubMed  Google Scholar 

  15. Low SWet al. p 53 status and the efficacy of cancer therapy in vivo.Science 1994;266: 807–810.

    Article  Google Scholar 

  16. Morgan WF, Day JP, Kaplan MI, McGhee EM, Limoli CL. Genomic instability induced by ionizing radiation.Radiat Res 1996;146: 247–258.

    Article  CAS  PubMed  Google Scholar 

  17. Brugarolas Jet al. Radiation induced cell cycle arrest compromised by p 21 deficiency.Nature 1995;377: 552–557.

    Article  CAS  PubMed  Google Scholar 

  18. Langley RE, Quartuccio SG, Kennealey PT, Coleman CN, Bump EA. Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation induced apoptosis in F9 teratocarcinoma cells.Radiat Res 1995;144: 90–96.

    Article  CAS  PubMed  Google Scholar 

  19. Yan JHet al. Management of local residual primary lesion of nasopharyngeal carcinoma: II. Results of prospective randomized trial on booster dose.Int J Radiat Oncol Biol Phys 1990;18: 295–298.

    Article  CAS  PubMed  Google Scholar 

  20. Sham JSTet al. Nasopharyngeal carcinoma. Patterns of tumor regression after radiotherapy.Cancer 1990;65: 216–220.

    Article  CAS  PubMed  Google Scholar 

  21. World Health Organisation.Handbook for Reporting Results of Cancer Treatment. WHO: Geneva, WHO Offset Publ. 48, 1979.

    Google Scholar 

  22. Anderson H. Ethyol and carboplatin thrombocytopenia in non small cell lung cancer. InCytoprotection in Cancer Therapy: Improving the Therapeutic Index of Cancer Treatment Ethyol Investigators Meeting, May 1998, Los Angeles, California, USA.

  23. Koukourakis MIet al. Fractionated carboplatin radiosensitization. A phase I dose escalation study.Am J Clin Oncol 1998;21: 595–601.

    Article  CAS  PubMed  Google Scholar 

  24. Koukourakis Met al. Weekly docetaxel and concomitant boost radiotherapy for non small cell lung cancer. A phase I/II dose escalation trial.Eur J Cancer 1998;34: 838–844.

    Article  CAS  PubMed  Google Scholar 

  25. Koukourakis MI, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulias V. Concurrent twice a week docetaxel and radiotherapy. A dose escalation trial with immunological toxicity evaluation.Int J Radiat Oncolo Biol Phys 1999;43: 107–114.

    Article  CAS  Google Scholar 

  26. Pronk LCet al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.J Clin Oncol 1997;15: 1071–1079.

    Article  CAS  PubMed  Google Scholar 

  27. Millward MJet al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non small cell lung cancer.J Clin Oncol 1997;15: 750–758.

    Article  CAS  PubMed  Google Scholar 

  28. Bookman MAet al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.J Clin Oncol 1996;14: 1895–1902.

    Article  CAS  PubMed  Google Scholar 

  29. Belani CP. Use of docetaxel and carboplatin for patients with non-small cell lung cancer.Oncology 1997;11(Suppl 7): 27–30.

    Google Scholar 

  30. Betticher DCet al. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non small cell lung cancer: A randomized phase II study.Br J Cancer 1995;72: 1551–1555.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Capizzi RL, Scheffler BJ, Schein PS. Amifostinee mediated protection of normal bone marrow from cytotoxic chemotherapy.Cancer 1993;72: 3495–3501.

    Article  CAS  PubMed  Google Scholar 

  32. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte colony stimulating factor and pre irradiation WR 2721 administration synergize to enhance hemopoietic reconstitution and increase survival.Int J Radiat Oncol Biol Phys 1992;22: 773–779.

    Article  CAS  PubMed  Google Scholar 

  33. de Graff Met al. Pharmacodynamic interactions between platinum and taxoid drugs on myeloid progenitor cells, human leucocytes and tumor cell lines.Proc Am Assoc Cancer Res 1998;39: 309.

    Google Scholar 

  34. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere).Neurology 1996;46: 108–111.

    Article  CAS  PubMed  Google Scholar 

  35. Hilkens PHet al. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.Br J Cancer 1997;75: 417–422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. van den Bent MJet al. Lhermitte's sign following chemotherapy with docetaxel.Neurology 1998;50: 563–564.

    Article  PubMed  Google Scholar 

  37. van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, van Houwelingen C, Neijt JP. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.Cancer 1990;66: 1697–1702.

    Article  PubMed  Google Scholar 

  38. McKeage MJ. Comparative adverse effect profiles of platinum drugs.Drug Saf 1995;13: 228–244.

    Article  CAS  PubMed  Google Scholar 

  39. Glover DJet al. Phase I/II trials with WR 2721 and cis platinum.Int J Radiat Oncol Biol Phys 1986;12: 1509–1512.

    Article  CAS  PubMed  Google Scholar 

  40. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy: risk factors, prognosis and protection by WR 2721.Cancer 1998;61: 2192–2195.

    Article  Google Scholar 

  41. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells.Cancer Res 1996;56: 1842–1850.

    CAS  PubMed  Google Scholar 

  42. Choy Het al. Radiation sensitizing effects of Taxotere.Proc Am Assoc Cancer Res 1992;33: 500.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiotherapy and Oncology, University Hospital of Heraklion, Iraklion, Crete, Greece

    M I Koukourakis & V Georgoulias

  2. Tumor and Angiogenesis Research Group, 18 Dimokratias Avenue, Iraklion, 71306, Crete, Greece

    M I Koukourakis, A Giatromanolaki, S Kalokyris, M Froudarakis & N Bahlitzanakis

  3. Schering-Plough SA, Athens, Greece

    G Retalis

  4. Department of Pneumology, Venizelion General Hospital, Iraklion, Crete, Greece

    N Bahlitzanakis

Authors
  1. M I Koukourakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Giatromanolaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Kalokyris
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Froudarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Georgoulias
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Retalis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Bahlitzanakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koukourakis, M.I., Giatromanolaki, A., Kalokyris, S. et al. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. Med Oncol 17, 135–143 (2000). https://doi.org/10.1007/BF02796209

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02796209

Keywords

Search

Navigation